A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Investigate the Efficacy and Safety of 2 Doses of Vipoglanstat in Patients With Moderate to Severe Endometriosis-related Pain - the NOVA Trial

The main objective of the trial is to evaluate the efficacy of vipoglanstat on endometriosis-related non-menstrual pelvic pain (NMPP).

开始日期2025-10-15

申办/合作机构

Gesynta Pharma AB

NCT04744207

/ Completed临床2期

A Phase II, Randomized, Multi-center, Placebo-controlled, Double-blind Study to Investigate the Safety of GS-248, and Efficacy on Raynaud's Phenomenon (RP) and Peripheral Vascular Blood Flow, in Subjects With Systemic Sclerosis (SSc)

The primary objective of this study is to determine the safety, and evaluate the efficacy of GS-248 versus placebo on Raynaud's Phenomenon (RP) in subjects with Systemic Sclerosis (SSc).

开始日期2020-12-29

申办/合作机构

Gesynta Pharma AB

[+1]

NCT04617509

/ Completed临床1期

An Open, One-sequence, Three-period Study in Healthy Subjects to Evaluate Pharmacokinetics and Food Effect After Oral Single Dosing of Two Different Solid Formulations of GS-248

The study will collect information about pharmacokinetics (PK), safety and tolerability following a single dose of GS-248 in two different oral solid formulations in capsules to healthy subjects. It will also collect information about pharmacokinetics (PK), safety and tolerability following a single dose of one of the two formulations of GS-248 in fed condition.

开始日期2020-03-31

申办/合作机构

Gesynta Pharma AB

[+2]

100 项与 Vipoglanstat 相关的临床结果

登录后查看更多信息

100 项与 Vipoglanstat 相关的转化医学

登录后查看更多信息

100 项与 Vipoglanstat 相关的专利（医药）

登录后查看更多信息

项与 Vipoglanstat 相关的文献（医药）

2025-02-01·Rheumatology (Oxford, England)

A phase 2 trial investigating the efficacy and safety of the mPGES-1 inhibitor vipoglanstat in systemic sclerosis-related Raynaud's

Article

作者: Pauling, John D ; Kowalski, Jan ; Krasowska, Dorota ; Denton, Christopher P ; Vonk, Madelon C ; Wojteczek, Anna ; Tornling, Göran ; Hall, Frances ; van Laar, Jacob M ; Bhat, Smita ; Anderson, Marina ; Murray, Andrea ; Edenius, Charlotte ; Olas, Jacek ; Olsson, Anna ; Herrick, Ariane L ; Korkosz, Mariusz ; Smith, Vanessa ; Del Galdo, Francesco

Abstract:

Objective:

Our objective was to test the hypothesis, in a double-blind, placebo-controlled study that vipoglanstat, an inhibitor of microsomal prostaglandin E synthase-1 (mPGES-1), which decreases prostaglandin E2 (PGE2) and increases prostacyclin biosynthesis, improves RP.

Methods:

Patients with SSc and ≥7 RP attacks during the last screening week prior to a baseline visit were randomized to 4 weeks treatment with vipoglanstat 120 mg or placebo. A daily electronic diary captured RP attacks (duration and pain) and Raynaud’s Condition Score, with change in RP attacks/week as the primary end point. Cold challenge assessments were performed at baseline and end of treatment. Exploratory end points included patients’ and physicians’ global impression of change, Assessment of Scleroderma-associated Raynaud’s Phenomenon questionnaire, mPGES-1 activity, and urinary excretion of arachidonic acid metabolites.

Results:

Sixty-nine subjects received vipoglanstat (n = 33) or placebo (n = 36). The mean weekly number of RP attacks [baseline; vipoglanstat 14.4 (S.D. 6.7), placebo 18.2 (12.6)] decreased by 3.4 (95% CI –5.8; –1.0) and 4.2 (–6.5; –2.0) attacks per week (P = 0.628), respectively. All patient-reported outcomes improved, with no difference between the groups. The mean change in recovery of peripheral blood flow after the cold challenge did not differ between the study groups. Vipoglanstat fully inhibited mPGES-1, resulting in 57% reduction of PGE2 and 50% increase of prostacyclin metabolites in the urine. Vipoglanstat was safe and well tolerated.

Conclusion:

Although vipoglanstat was safe, and well tolerated in a dose achieving full inhibition of mPGES-1, it was ineffective in SSc-related RP. Further development and evaluation of vipoglanstat will therefore be in other diseases where mPGES-1 plays a pathogenetic role.

Trial registration:

ClinicalTrials.gov, https://www.clinicaltrials.gov, NCT0474420.

2021-12-01·Journal of translational medicine2区 · 医学

Inhibition of microsomal prostaglandin E synthase-1 ameliorates acute lung injury in mice

2区 · 医学

ArticleOA

作者: Doods, Henri ; Pekcec, Anton ; Wu, Dongmei ; Nasseri, Saeed ; Feng, Huiying ; Lee, Dongwon ; Gurusamy, Malarvizhi ; Rampa, Dileep Reddy

Abstract:

Background:

To examine the effects of BI 1029539 (GS-248), a novel selective human microsomal prostaglandin E synthase-1 (mPGES-1) inhibitor, in experimental models of acute lung injury (ALI) and sepsis in transgenic mice constitutively expressing the mPGES1 (Ptges) humanized allele.

Methods:

Series 1: Lipopolysaccharide (LPS)-induced ALI. Mice were randomized to receive vehicle, BI 1029539, or celecoxib. Series 2: Cecal ligation and puncture-induced sepsis. Mice were randomized to receive vehicle or BI 1029539.

Results:

Series 1: BI 1029539 or celecoxib reduced LPS-induced lung injury, with reduction in neutrophil influx, protein content, TNF-ɑ, IL-1β and PGE2 levels in bronchoalveolar lavage (BAL), myeloperoxidase activity, expression of mPGES-1, cyclooxygenase (COX)-2 and intracellular adhesion molecule in lung tissue compared with vehicle-treated mice. Notably, prostacyclin (PGI2) BAL concentration was only lowered in celecoxib-treated mice. Series 2: BI 1029539 significantly reduced sepsis-induced BAL inflammatory cell recruitment, lung injury score and lung expression of mPGES-1 and inducible nitric oxide synthase. Treatment with BI 1029539 also significantly prolonged survival of mice with severe sepsis. Anti-inflammatory and anti-migratory effect of BI 1029539 was confirmed in peripheral blood leukocytes from healthy volunteers.

Conclusions:

BI 1029539 ameliorates leukocyte infiltration and lung injury resulting from both endotoxin-induced and sepsis-induced lung injury.

2019-12-01·FASEB journal : official publication of the Federation of American Societies for Experimental Biology2区 · 生物学

Inhibition of human microsomal PGE2 synthase‐1 reduces seizure‐induced increases of P‐glycoprotein expression and activity at the blood‐brain barrier

2区 · 生物学

Article

作者: Pekcec, Anton ; Hosoya, Ken‐Ichi ; Kryscio, Richard J. ; Doods, Henri ; Akanuma, Shin‐Ichi ; Hartz, Anika M. S. ; Bauer, Björn ; Soldner, Emma L. B.

The cause of antiseizure drug (ASD) resistance in epilepsy is poorly understood. Here, we focus on the transporter P‐glycoprotein (P‐gp) that is partly responsible for limited ASD brain uptake, which is thought to contribute to ASD resistance. We previously demonstrated that cyclooxygenase‐2 (COX‐2) and the prostaglandin E receptor, prostanoid E receptor subtype 1, are involved in seizure‐mediated P‐gp up‐regulation. Thus, we hypothesized that inhibiting microsomal prostaglandin E 2 (PGE2) synthase‐1 (mPGES‐1), the enzyme generating PGE2, prevents blood‐brain barrier P‐gp up‐regulation after status epilepticus (SE). To test our hypothesis, we exposed isolated brain capillaries to glutamate ex vivo and used a combined in vivo‐ex vivo approach by isolating brain capillaries from humanized mPGES‐1 mice to study P‐gp levels. We demonstrate that glutamate signaling through the NMDA receptor, cytosolic phospholipase A2, COX‐2, and mPGES‐1 increases P‐gp protein expression and transport activity levels. We show that mPGES‐1 is expressed in human, rat, and mouse brain capillaries. We show that BI1029539, an mPGES‐1 inhibitor, prevented up‐regulation of P‐gp expression and transport activity in capillaries exposed to glutamate and in capillaries from humanized mPGES‐1 mice after SE. Our data provide key signaling steps underlying seizure‐induced P‐gp up‐regulation and suggest that mPGES‐1 inhibitors could potentially prevent P‐gp up‐regulation in epilepsy.—Soldner, E. L. B., Hartz, A. M. S., Akanuma, S.‐I., Pekcec, A., Doods, H., Kryscio, R. J., Hosoya, K.‐I., Bauer, B. Inhibition of human microsomal PGE2 synthase‐1 reduces seizure‐induced increases of P‐glycoprotein expression and activity at the blood‐brain barrier. FASEB J. 33, 13966‐13981 (2019). www.fasebj.org

项与 Vipoglanstat 相关的新闻（医药）

2025-12-04

·孕育前线

子宫内膜异位症的治愈之路何在？

子宫内膜异位症，这一影响全球约1.9亿女性与女孩的疾病，始终面临着“研究不足、无药可愈”的困境。其核心病理是子宫内膜样组织在子宫外异常增殖，引发剧烈盆腔疼痛、月经过多，更有50%的患者会遭遇生育难题。尽管它困扰着十分之一的育龄人群，但其研究关注度与资金支持却长期处于“被忽视”状态——美国国立卫生研究院对糖尿病、乳腺癌的 funding 分别是它的15倍和30倍，即便是罕见病克罗恩病，每位患者获得的研究资金也高达其65倍。这种资源失衡导致患者平均需等待8年才能确诊，而现有激素疗法无法解决不孕，手术切除病灶的复发率更是高达50%，每年仅美国就因此产生780亿至1200亿美元的经济损失。值得欣慰的是，近年来该领域的研究终于迎来转机，不仅多款创新药物进入临床阶段，Dim（二吲哚甲烷）与生育酶等新兴方向也逐渐进入科研视野，为患者带来新的希望。研究困局：资金匮乏下的临床挑战 Hera Biotech联合创始人Bruce Nicholson直言，研究资金的长期短缺是子宫内膜异位症治疗进展缓慢的关键。2025年Organon公司的OG-6219二期试验失败，更是给患者群体带来沉重打击——这款靶向HSD17B1酶的小分子药物，本希望通过抑制子宫壁组织异常生长缓解疼痛，却因未达主要终点被迫终止开发。但困境之下，行业对女性健康的关注度正在觉醒。Gesynta Pharma完成2700万美元B轮融资、Cyclana Bio筹集500万英镑用于药物研发，这些投资信号预示着女性医疗保健领域的变革。正如Innovestor合伙人Pekka Simula所言：“大型制药公司终于意识到，世界一半人口是女性。” 药物突破：口服制剂与靶向疗法的崛起 Linzagolix：口服给药革新治疗体验 2025年，日本Kissei公司研发的linzagolix成为焦点——继英国NHS批准后，该药又在中国台湾获批，不仅适用于子宫肌瘤，更为子宫内膜异位症患者提供了便捷的治疗选择。作为促性腺激素释放激素受体拮抗剂，它能阻断与病灶生长相关的激素过量分泌，搭配低剂量激素替代疗法，可在显著缓解痛经与盆腔疼痛的同时，避免更年期症状和骨质流失。与传统注射类药物不同，这款每日一次的口服药片让患者无需频繁往返诊所，真正实现了“居家掌控健康”。此前，英国与欧盟批准的口服药物relugolix（商品名Ryeqo）已开创先河，其将GnRH受体拮抗剂与附加疗法合二为一的设计，同样为患者带来了便利。两款口服制剂的接连获批，标志着子宫内膜异位症治疗正在告别“注射依赖”。 HMI-115：非激素靶点的疼痛克星上海和其瑞医药的HMI-115在二期试验中取得重大突破，这款单克隆抗体以催乳素受体为靶点，实现了“不干扰性激素却能缓解疼痛”的突破。试验数据显示，它能使痛经疼痛减轻42%，非经期盆腔疼痛下降52%。北京协和医院妇科主任朱兰指出，催乳素受体过度表达与子宫内膜异位症密切相关，且高催乳素水平会降低女性疼痛阈值，而HMI-115通过阻断该受体，既避免了更年期副作用，又不会影响生育功能，有望彻底改变治疗模式。目前，该药已计划启动全球三期试验。 Vipoglanstat：抑制炎症的小分子新贵瑞典Gesynta Pharma的vipoglanstat获英国药监局批准进入二期临床试验。这款小分子药物通过抑制特定酶的活性，减少促炎分子前列腺素E2的生成，从而阻断病灶进展与疼痛传导。临床前研究已证实其能有效下调子宫内膜异位病灶，而2700万美元的融资则为其临床推进提供了有力支撑。跨界探索：老药新用与天然疗法的潜力二氯乙酸：癌症药物的“跨界尝试”子宫内膜异位症患者体内会过量产生乳酸，这种代谢副产品会加速异常细胞增殖。研究发现，常用于治疗癌症的二氯乙酸能有效降低乳酸水平，抑制病灶扩散。爱丁堡大学的动物实验显示，该药可使病灶在七天内缩小，目前已进入人体临床试验阶段，为“老药新用”提供了典型范例。大麻：疼痛管理的新可能澳大利亚西悉尼大学正在开展双盲随机对照试验，探索药用大麻对子宫内膜异位症疼痛的缓解作用。早期研究显示，59%的患者使用大麻后可摆脱止痛药依赖，其机制可能与调节内源性大麻素系统、抑制炎症相关。Ananda Pharma的MRX1 CBD候选药物也已启动临床试验，计划在100名患者中验证其镇痛效果。新兴方向：Dim与生育酶的研究新视角在创新药物不断涌现的同时，Dim（二吲哚甲烷）与生育酶的相关研究为子宫内膜异位症治疗开辟了新路径。Dim是十字花科蔬菜中的天然活性成分，研究发现其具有调节雌激素代谢、抑制异常细胞增殖的作用——子宫内膜异位症的发生与雌激素失衡密切相关，Dim可通过调节芳香化酶活性，减少雌激素对异位病灶的刺激，同时增强机体抗氧化能力，减轻盆腔炎症反应，为缓解疼痛和延缓病灶进展提供辅助支持。而生育酶的作用则聚焦于患者的生育难题。子宫内膜异位症患者常存在输卵管纤毛运动异常、盆腔微环境紊乱等问题，导致受精与着床困难。相关研究表明，补充特定生育酶（如透明质酸酶、菠萝蛋白酶等）可改善盆腔局部血液循环，降解粘连组织与炎性渗出物，优化生殖系统微环境；同时，这些酶类还能调节子宫内膜容受性，增强卵子与精子的结合能力，为有生育需求的患者提供新的辅助治疗思路。目前，关于Dim与生育酶联合应用于子宫内膜异位症的临床研究正在推进，有望为患者提供“控痛+助孕”的双重解决方案。诊断革新：早发现才能早干预治疗的突破离不开诊断技术的支撑。子宫内膜异位症拖延诊断时间越长，病灶侵袭越严重，可能引发瘢痕组织、粘连、囊肿等并发症，增加治疗难度。法国Ziwig公司的Endotest诊断器械，通过检测唾液中的microRNA（子宫内膜异位症中会出现失调），实现了便捷无创的筛查；巴黎Endogene Bio推出的经血检测方法，可在数周内完成诊断，为早期干预提供了可能。这些创新工具的出现，有望缩短诊断周期，让患者在病情初期就能获得有效治疗。总结：困境中突围，希望在前方尽管OG-6219的失败仍让人惋惜，但linzagolix、HMI-115等药物的获批与推进，Dim、生育酶等新兴方向的探索，以及诊断技术的革新，都预示着子宫内膜异位症的治疗格局正在改变。随着女性健康关注度的提升、研究资金的增加，曾经“被忽视”的领域正迎来前所未有的发展机遇。未来，随着多靶点药物、跨界疗法与辅助干预手段的深度融合，有望为患者提供兼具“控痛、抑灶、保生育”的综合解决方案，让这一致衰性疾病不再成为女性健康的“绊脚石”。相关阅读腺肌、内异症整体自然疗法，一条自救之路逆转子宫内膜异位症不孕的5个步骤子宫腺肌症、内膜异位症、肌瘤不想开刀，这招全身酶疗法送给有缘人解锁8大秘密武器：自然舒缓子宫内膜异位症&腺肌症疼痛 Endok™宫巢净化三剑客+草本茶：生殖系统深度净化调养

2025-11-13

·PRNewswire

Clarivate Companies to Watch Report Spotlights Seven Women's Health Startups Shaping the Future of Care

Report highlights emerging biotech innovators advancing new therapies, equity and investment across reproductive, chronic and mental health LONDON, Nov. 13, 2025 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today released its latest Companies to Watch report, Rediscovering Women's Health, highlighting seven companies driving innovation across reproductive care, chronic disease and mental health. Drawing on proprietary data, expert analysis and insights into therapeutic impact, financing activity and R&D momentum, the report showcases why these companies are recognized as high-impact innovators. Despite representing half the global population, women remain underrepresented in clinical research and healthcare investment, with women's health accounting for just 15% of venture capital and 5% of global healthcare R&D funding. Rediscovering Women's Health highlights organizations addressing these gaps through inclusive research, novel therapies and a deeper understanding of female-specific conditions such as early menopause, polycystic ovary syndrome (PCOS) and endometriosis, factors that influence broader outcomes like cardiovascular disease and dementia. The report also highlights growing momentum in women's health R&D. Anne Lecocq, SVP and GM, R&D, Life Sciences & Healthcare, Clarivate, said: "Women's health is no longer being defined solely by reproductive care; it's being reframed through a broader lens that recognizes how biological and social factors shape outcomes across every therapeutic area. This shift marks a pivotal moment for the industry, as data-driven innovation and inclusive research begin to translate into more equitable care and better health outcomes for women worldwide. By spotlighting organizations driving this change, the Companies to Watch report underscores how scientific insight and investment can work together to close persistent gaps and advance women's health globally." Agnès Arbat, MD, Co-Founder and CEO, Oxolife, said: "The next era of women's health innovation will be defined by science that recognizes women's unique biology as the foundation for discovery. Across the industry, we're seeing a long-overdue shift toward inclusive research and smarter, more targeted therapies that can truly transform outcomes for women." These companies are pioneering solutions that challenge outdated paradigms and promote equitable care. Clarivate analysts reviewed deal valuations, clinical trials, patents and market approvals to identify seven Companies to Watch in the space: Daré Bioscience (USA): focused on accelerating innovation in women's health by delivering evidence-based solutions that address long-standing unmet needs across contraception, sexual and vaginal health, pelvic pain, fertility, infectious disease and menopause. Freya™ Biosciences (Denmark/USA): leveraging its DYSCOVER™ multi-omics platform to develop microbial immunotherapies, including investigational vaginal therapy FB301, targeting chronic inflammation in female reproductive diseases and improving IVF outcomes. Gesynta Pharma (Sweden): developing treatments for chronic inflammation and pain, including lead candidate vipoglanstat, a non-hormonal, non-opioid, disease-modifying therapy for endometriosis. Granata Bio Corporation (USA): dedicated to advancing reproductive health by developing fertility treatments that expand options, improve access and affordability and drive innovation. Hope Medicine (Mainland China): developing therapies for endocrine, cardiovascular, and metabolic diseases, with a special focus on women's health, including lead asset HMI-115 targeting prolactin signaling to treat endometriosis, alopecia and related conditions. Oxolife (Spain): developing OXO-001 to improve fertility and live birth rates by enhancing embryo implantation, restoring ovulation, improving metabolic health and reducing pregnancy loss. Reunion Neurosciences (USA): developing psychedelic-inspired therapies, with lead candidate RE104 targeting postpartum depression and adjustment disorders to provide fast-acting benefits with limited psychoactive effects. Greater awareness, stronger regulatory frameworks supporting sexual health equity and increasing financial investment are accelerating progress in women's health. These developments create meaningful opportunities for the pharmaceutical industry to help close long-standing gaps and address unmet health needs for women worldwide. Learn more about emerging innovations and the seven companies shaping the future of women's health in the full Companies to Watch report, Rediscovering Women's Health, here. Methodology for the Companies to Watch Report Clarivate analysts employed a rigorous, multidimensional framework to identify the emerging innovators featured in this Companies to Watch report. Each company was assessed for its ability to address critical scientific, clinical and business challenges within the women's health space. Key considerations included demonstrated proof of concept, achievement of developmental milestones and positioning within the clinical trial landscape. The evaluation also factored in the strength of collaborations with leading academic and research institutions, the potential to address significant unmet medical needs and the overall burden of disease targeted by each therapy. Financial health was a further determinant, with analysts examining capital raised, investor partnerships, projected runway and prospects for future growth through fundraising or strategic alliances. Finally, each company's intellectual property estate was analyzed to understand the strength and breadth of its innovation pipeline. The assessment was underpinned by insights from Clarivate's trusted proprietary data sources, including Cortellis Competitive Intelligence, Cortellis Deals Intelligence, Cortellis Regulatory Intelligence, Cortellis Clinical Trials Intelligence and BioWorld, ensuring a holistic view of the companies poised to shape the future of precision oncology. About Clarivate Clarivate is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit clarivate.com. Media Contact: Catherine Daniel Director, External Communications, Life Sciences & Healthcare [email protected] SOURCE Clarivate Plc 21% more press release views with Request a Demo

临床研究

2025-05-06

·orexo.com

Orexo Q1 2025 Interim Report

Q1 2025 highlights › Total net revenues of SEK 146.2 m (139.3) › EBITDA of SEK 5.9 m (15.9) › Net earnings of SEK -15.9 m (-8.9) › US Commercial segment net revenues of SEK 133.0 m (129.3), in local currency USD 12.5 m (12.4) › Cash flow from operating activities of SEK 32.9 m (-18.9), cash and cash equivalents of SEK 119.1 m (198.0) › Earnings per share before and after dilution amounted to SEK -0.46 (-0.26) › Positive topline data showed from clinical study of OX640, a nasal powder-based epinephrine product, in participants with allergic rhinitis › Future rights to royalties for OX-MPI, a new treatment for endometriosis, converted to shares in Gesynta Pharma valued at SEK 19 m. Important events after the end of the period › Orexo in collaboration with Abera Bioscience announced positive in-vivo data for powder-based intranasal vaccine formulated with the AmorphOX® technology. CEO comments in brief: Stable commercial business in a volatile market I’m pleased to report a stable start to 2025 from financial and product development perspectives. Our financial results in the quarter are in line with our expectations, including a positive EBITDA and only a slight decline in our cash position, caused solely by a weakening of the USD in March. Cash flow from operations is positive and have improved since last year. This is pleasing given that the first quarter can often be a challenging period, characterised by inventory reductions at wholesalers and a recurring seasonal decline in market demand due to resetting of deductibles, and formulary changes. We’re continuing to work with our nasal device supplier. As we’re yet to have a firm delivery date for the device, we’re now looking to resubmit OX124 to the FDA in mid-2026. Interest in OX640 from potential partners has increased since we in January reported positive results from our second OX640 clinical study, where we showed strong potential for a differentiated product. Uppsala, Sweden, May 6 2025 Nikolaj Sørensen President and CEO For full CEO comments see attached PDF. Contact persons quarterly report Nikolaj Sørensen, President and CEO Fredrik Järrsten, EVP and CFO Lena Wange, IR & Communications Director Tel: +46 18 780 88 00, +1 855 982 7658 E-mail: ir@orexo.com Presentation On May 6, at 2 pm CEST analysts, investors and media are invited to attend a presentation, incl. a Q&A. To attend via teleconference where you can ask questions verbally: Use this link (1): Orexo Q1 Report 2025 When registered you will be provided phone numbers and a conference ID to access the conference. To attend via webcast: Use this link (2): Orexo Q1 Report 2025 Prior to the call, presentation material will be available on the website under Investors/Rapport archive. This information is information that Orexo AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-05-06 08:00 CEST. Attachments Orexo Interim Report Q1 2025 May 5

临床结果疫苗财报

100 项与 Vipoglanstat 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
子宫内膜异位症	临床2期	保加利亚	Gesynta Pharma AB	2025-10-15
子宫内膜异位症	临床2期	波兰	Gesynta Pharma AB	2025-10-15
子宫内膜异位症	临床2期	英国	Gesynta Pharma AB	2025-10-15
微血管疾病	临床2期	美国	Orexo US, Inc.	2022-01-30
微血管疾病	临床2期	美国	Gesynta Pharma AB	2022-01-30
雷诺病	临床2期	比利时	Gesynta Pharma AB	2020-12-29
雷诺病	临床2期	荷兰	Gesynta Pharma AB	2020-12-29
雷诺病	临床2期	波兰	Gesynta Pharma AB	2020-12-29
雷诺病	临床2期	英国	Gesynta Pharma AB	2020-12-29
视网膜色素变性	临床2期	比利时	Gesynta Pharma AB	2020-12-29

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04744207 (CTgov)	临床2期	雷诺病 \| 系统性硬皮病 \| 视网膜色素变性	94	GS-248 (GS-248)	餘選積獵艱鹹醖夢鬱糧(鑰顧製淵範夢積遞鬱醖) = 憲獵製糧獵廠衊夢網繭壓襯獵齋積艱鏇鬱繭構 (廠餘願鑰蓋簾鑰蓋製製, 窪糧簾網壓蓋鹹衊醖餘 ~ 鏇夢遞壓衊範窪獵餘蓋) 更多	-	2024-08-09
				Placebo (Placebo)	餘選積獵艱鹹醖夢鬱糧(鑰顧製淵範夢積遞鬱醖) = 積壓顧艱鹹蓋齋蓋鹹製壓襯獵齋積艱鏇鬱繭構 (廠餘願鑰蓋簾鑰蓋製製, 鹹壓繭齋齋繭遞獵夢醖 ~ 遞鏇夢選顧鏇鹹醖餘膚) 更多
NCT04617509 (CTgov)	临床1期	-	14	GS-248 (Part I GS-248 Formulation A)	窪鏇簾餘齋醖窪淵衊憲(範膚獵鑰壓鏇餘壓夢襯) = 繭襯顧鹽鏇範窪蓋簾選壓觸築獵餘衊築選繭憲 (製鑰積齋築獵襯蓋範積, 220.9) 更多	-	2021-08-31
				Formulation B GS-248 (Part I GS-248 Formulation B)	窪鏇簾餘齋醖窪淵衊憲(範膚獵鑰壓鏇餘壓夢襯) = 構鏇獵鏇網構蓋鑰淵顧壓觸築獵餘衊築選繭憲 (製鑰積齋築獵襯蓋範積, 219.1) 更多